Aarkstore - Glycine Transporter Type-1 (Glyt-1) Inhibitors -Pipeline Insights, 2014

1
Glycine Transporter Type-1 (Glyt-1) Inhibitors
-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/pharmaceuticals-healthcar
  e/73731/glycine-transporter-type-1-glyt-1-inhibito
  rs-pipeline-insights-2014

2
Summary

• DelveInsights,Glycine Transporter Type-1 (Glyt-1)
  Inhibitors-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this mechanism of action (MOA). A
  key objective of the report is to establish the
  understanding for all the pipeline drugs that
  fall under Glycine Transporter Type-1 (Glyt-1)
  Inhibitors. This report provides information on
  the therapeutic development based on the Glycine
  Transporter Type-1 (Glyt-1) Inhibitors dealing
  with mechanism of action, comparative analysis at
  various stages covering Filed, Phase III, Phase
  II, Phase I, IND filed, Preclinical, Discovery
  and unknown stages, therapeutics assessment by
  monotherapy and combination products and molecule
  type drug information. The report also covers the
  companies information involved in the therapeutic
  development of the products. It also has
  highlighted the discontinued and dormant products.

3
Summary

• Data Sources
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.Secondary
  sources information and data has been collected
  from various printable and non-printable sources
  like search engines, News websites, Government
  Websites, Trade Journals, White papers,
  Magazines, Trade associations, Books, Industry
  Portals, Industry Associations and access to
  available databases.Please note this report
  requires certain updates. We have all the
  information available but require 3 business days
  to complete the process and ensure it is as
  up-to-date as possible. Certain sections in the
  report may be removed or altered based on the
  availability and relevance of data for the
  indicated mechanism of action. 

4
Summary

• Scope 
• The report provides a snapshot of the global
  therapeutic landscape of Glycine Transporter
  Type-1 (Glyt-1) InhibitorsThe report provides
  pipeline products under drug profile section
  which includes product description, MOA,
  licensors collaborators, development partner
  and chemical informationCoverage of the Glycine
  Transporter Type-1 (Glyt-1) Inhibitors pipeline
  on the basis of target, MOA, route of
  administration, technology involved and molecule
  typeThe report reviews key players involved in
  the therapeutics development for Glycine
  Transporter Type-1 (Glyt-1) Inhibitors and also
  provide company profilingThe report also gives
  the information of dormant and discontinued
  pipeline projects Pipeline products coverage
  based on various stages of development ranging
  from preregistration till discovery and
  undisclosed stages Provides pipeline assessment
  by monotherapy and combination therapy products,
  stage of development and molecule type

5
Summary

• Reasons to buyComplete MOA intelligence and
  complete understanding over therapeutics
  development for Glycine Transporter Type-1
  (Glyt-1) InhibitorsIdentify the relationship
  between the drugs and use it for target finding,
  drug repurposing, and precision medicine.Devise
  corrective measures for pipeline projects by
  understanding Glycine Transporter Type-1 (Glyt-1)
  Inhibitors pipeline depth and focus of Indication
  therapeutics Developing strategic initiatives to
  support your drug development activities.Optimize
  your portfolio and keep you in touch with the
  rapidly changing pharmaceutical markets, and make
  the best decisions for your business.

6
Summary

• Develop and design in licensing and out licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and ScopeProvides
  strategically significant competitor information,
  analysis, and insights to formulate effective RD
  development strategies Modify the therapeutic
  portfolio by identifying discontinued projects
  and understanding the factors that drove them
  from pipelineGaining a Full Picture of the
  Competitive Landscape for Evidence based Decisions

7
Table of Content

• Glycine Transporter Type-1 (Glyt-1) Inhibitors
  OverviewGlycine Transporter Type-1 (Glyt-1)
  Inhibitors Disease AssociatedGlycine Transporter
  Type-1 (Glyt-1) Inhibitors Pipeline
  TherapeuticsGlycine Transporter Type-1 (Glyt-1)
  Inhibitors Therapeutics under Development by
  Companies Glycine Transporter Type-1 (Glyt-1)
  Inhibitors Late Stage Products (Filed and Phase
  III)Comparative Analysis Glycine Transporter
  Type-1 (Glyt-1) Inhibitors Mid Clinical Stage
  Products (Phase II)Comparative Analysis Glycine
  Transporter Type-1 (Glyt-1) Inhibitors Early
  Clinical Stage Products (Phase I and IND
  Filed)Comparative Analysis Glycine Transporter
  Type-1 (Glyt-1) Inhibitors Discovery and
  Pre-Clinical Stage Products Comparative
  Analysis Drug Candidate Profiles

8
Table of Content

• Glycine Transporter Type-1 (Glyt-1) Inhibitors
  Therapeutics Assessment Assessment by
  Monotherapy Products Assessment by Combination
  Products Assessment by Route of
  Administration Assessment by Molecule
  Type Glycine Transporter Type-1 (Glyt-1)
  Inhibitors Discontinued Products Glycine
  Transporter Type-1 (Glyt-1) Inhibitors Dormant
  ProductsCompanies Involved in Therapeutics
  Development for Glycine Transporter Type-1
  (Glyt-1) Inhibitors Appendix Methodology Contac
  t Us Disclaimer

9
List of Tables

• Number of Products under Development for Glycine
  Transporter Type-1 (Glyt-1) Inhibitors by Therapy
  Area, 2014Number of Products under Development
  for Glycine Transporter Type-1 (Glyt-1)
  Inhibitors, 2014Number of Products under
  Development by Companies Comparative Analysis by
  Late Clinical Stage Products (Filed and Phase
  III), 2014Comparative Analysis Mid Clinical
  Stage Products (Phase II), 2014Comparative
  Analysis Early Clinical Stage Products (Phase I
  and IND Filed), 2014Comparative Analysis
  Discovery and Pre-Clinical Stage Products,
  2014Drug Candidates Profiles

10
List of Tables

• Glycine Transporter Type-1 (Glyt-1) Inhibitors
  Assessment by Monotherapy Products Glycine
  Transporter Type-1 (Glyt-1) Inhibitors Assessment
  by Combination Products Glycine Transporter
  Type-1 (Glyt-1) Inhibitors Assessment by Route of
  Administration Glycine Transporter Type-1
  (Glyt-1) Inhibitors Assessment by Stage and Route
  of Administration Glycine Transporter Type-1
  (Glyt-1) Inhibitors Assessment by Molecule
  Type Glycine Transporter Type-1 (Glyt-1)
  Inhibitors Assessment by Stage and Molecule
  Type Glycine Transporter Type-1 (Glyt-1)
  Inhibitors Therapeutics Discontinued
  Products Glycine Transporter Type-1 (Glyt-1)
  Inhibitors Therapeutics Dormant ProductsProducts
  under Development by Companies, 2014

11
List of Figures

• Number of Products under Development for Glycine
  Transporter Type-1 (Glyt-1) Inhibitors by Therapy
  Area, 2014Number of Products under Development
  for Glycine Transporter Type-1 (Glyt-1)
  Inhibitors, 2014Late Clinical Stage Products
  (Filed and Phase III), 2014Mid Clinical Stage
  Products (Phase II), 2014Early Clinical Stage
  Products (Phase I and IND Filed), 2014Discovery
  and Pre-Clinical Stage Products, 2014Glycine
  Transporter Type-1 (Glyt-1) Inhibitors Assessment
  by Monotherapy Products Glycine Transporter
  Type-1 (Glyt-1) Inhibitors Assessment by
  Combination Products Glycine Transporter Type-1
  (Glyt-1) Inhibitors Assessment by Route of
  Administration Glycine Transporter Type-1
  (Glyt-1) Inhibitors Assessment by Stage and Route
  of Administration Glycine Transporter Type-1
  (Glyt-1) Inhibitors Assessment by Molecule
  Type Glycine Transporter Type-1 (Glyt-1)
  Inhibitors Assessment by Stage and Molecule Type

12
Related Reports

• 2015 Worldwide Medical Laboratories
  Industry-Industry Market Report
• 2015 Worldwide Pharmaceutical Preparation Mfg.
  Industry-Industry Market Report
• OncoPlex Diagnostics - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• MetaStat, Inc. - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Advanced Cell Diagnostics, Inc. - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• Ascension Health - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Accretive Health, Inc. (ACHI) - Strategic SWOT
  Analysis Review
• Jazz Pharmaceuticals plc (JAZZ) - Financial and
  Strategic SWOT Analysis Review
• Pharmstandard (PHST) - Financial and Strategic
  SWOT Analysis Review
• GLG Life Tech Corporation (GLG) - Financial and
  Strategic SWOT Analysis Review

13

• Glycine Transporter Type-1 (Glyt-1) Inhibitors
  -Pipeline Insights, 2014
• Published Dec. 2014 60 Pages
• DelveInsights,Glycine Transporter Type-1 (Glyt-1)
  Inhibitors-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this mechanism of action (MOA).
  
  Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news